AltruBio lands up to $225M after shift to immune drug research
BioPharma
Source: biopharmadive.com
📰 Amgen News
Page 39 - Amgen News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Amgen. Real-time updates on events, politics, business and more.
Dr. Reddy's Laboratories leverages strategic collaborations for access, growth and Innovation
Dr. Reddys strategic focus on innovation-led growth, underpinned by robust partnerships and collaborations, is more than a business strategy; it is a mission to improve healthcare outcomes across India.
United Kingdom Hengrui Pharma Junshi Biosciences Reddy Laboratories Ltd Nestle Health Science Pharmazz Inc
Source: ibtimes.co.in
Wyden turns to Pfizer in ongoing tax probe
The senator inked a letter to Pfizer's CEO asking for information relating to the sharp drop in the company's effective tax rate.
Source: fiercepharma.com
By 2030, AstraZeneca Expects To Generate $80 Billion In Total Revenue
(CTN News) - AstraZeneca, a multinational pharmaceutical corporation, made the announcement on Tuesday that it planned to boost its...............
Source: chiangraitimes.com
Dai ichi Life Insurance Company Ltd Increases Position in Amgen Inc. (NASDAQ:AMGN)
Dai ichi Life Insurance Company Ltd raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 40.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 99,957 shares of the medical research company’s stock after buying an additional 28,999 […]
United States Nancya Grygiel Wealthplan Investment Management Asset Management North America Corp Exchange Commission Life Insurance Company Ltd
Source: wkrb13.com
AstraZeneca: Phase 2 endpoint not met in COPD
AstraZeneca announced on Monday that a phase 2 clinical trial of Tezspire, its new asthma treatment, failed to meet its primary endpoint in chronic obstructive pulmonary disease .Initial results from...
Source: marketscreener.com
GLP-1 Receptor Agonist Market to Reach $125B by 2033: GlobalData
While Eli Lilly and Novo Nordisk currently dominate the GLP-1 receptor agonist space, there are more than 50 candidates in clinical development for obesity and type 2 diabetes, according to analytics firm GlobalData.
Source: biospace.com
Amgen's Imdelltra granted FDA accelerated approval to treat small cell lung cancer
More than 234,000 new cases of lung cancer are expected to be diagnosed in the US this year
Source: pmlive.com
AZ, Amgen's asthma biologic Tezspire excels in trial for COPD
Amgen and AstraZeneca have reported data from a trial that showed the effectiveness of their asthma drug Tezspire in certain patients with COPD.
Source: fiercepharma.com
BI Asset Management Fondsmaeglerselskab A S Trims Position in Amgen Inc. (NASDAQ:AMGN)
BI Asset Management Fondsmaeglerselskab A S decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 22.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 152,750 shares of the medical research company’s stock after selling 44,021 shares during the period. Amgen makes […]
Source: dailypolitical.com